Background: Platelet-Rich Plasma (PRP) is a non-invasive modality that has been used to treat
Introduction
Low back pain (LBP) is one of the most common musculoskeletal issues, affecting over 25 million Americans, and costing in excess of 102 billion dollars each year [1] [2] [3] [4] . Lifetime prevalence of LBP has been estimated to be as high as 84% [3] . However, chronic LBP that is defined as pain that lasts greater than 3 months is reported to have a 23% prevalence [5] . LBP may originate from multiple underlying etiologies creating a challenge for physicians. This uncertainty accounts for the continued rise in treatment costs without a similar increase in the number of office visits associated with LBP [4] . General recommendations for the treatment of LBP begins by ruling out serious pathoanatomical causes, such as spinal disease or radiculopathies, thereby leading to a diagnosis of non-specific back pain [5] .
Magnetic resonance imaging (MRI) is used to rule out serious etiologies; however, it is not recommended for non-specific LBP due to a lack of evidence of improved symptoms and high false positives rates [6] [7] [8] [9] . Studies have shown that abnormal MRI findings are present in up to 90% of asymptomatic patients due to normal aging and lead to unnecessary treatments that carry increased risks of adverse complications or side effects [6] [7] [8] [9] . Despite recommendations, MRI orders for LBP continue to increase with a parallel increase in the rates of narcotic prescriptions, epidural steroid injections and surgical interventions, without an improvement in self-reported health status [2, 8, [10] [11] [12] [13] [14] [15] .
A c c e p t e d M a n u s c r i p t Platelet-rich plasma (PRP) therapy is a non-invasive, nonsurgical biologic intervention that has gained attention in the treatment of degenerative and musculoskeletal conditions [16, 17] . PRP is isolated from autologous blood and contains an assortment of signaling cytokines that modulate inflammation and angiogenesis as well cell migration and proliferation, all of which are important in the healing process [18] [19] [20] [21] . Studies have also found that PRP effects gene expression and downstream processes that produce pain. Thereby, PRP may play role in reducing or modulating the amount of pain produced by the body [22] . Due to these properties, patients with chronic non-specific LBP may experience therapeutic effects from PRP therapy.
It is well documented in research that PRP has demonstrated increased tendon and ligament healing through injections [23] . At our clinic we inject PRP into the muscles, fascia, and ligaments surrounding the lumbar spine to improve patients' spinal stability. Many of our patients may be diagnosed with herniated discs, facet arthropathy, degenerative disc disease, spinal stenosis, scoliosis, spondylosis, spondylolisthesis, or other pathology. We have found that the actual pain generator may not even be noted in the diagnosis. Strengthening the support of the spine may not only relieve patients' current pain regardless of the diagnosis but may lower their risk for future discogenic problems.
To our knowledge, PRP research for LBP has primarily focused on discogenic etiology.
The goal of our study was to determine the therapeutic effect of PRP therapy for chronic nonspecific LBP regardless of the diagnosis. Determining the clinical efficacy of PRP for the reduction of low back pain is essential to improve patient outcomes and prevent unnecessary and risky treatments.
Methods

Patients
A c c e p t e d M a n u s c r i p t This study reports clinical practice outcomes in which variables were administered prospectively and data were analyzed retrospectively. Patients who were included in this study underwent a series of one, two, or three PRP treatments for lower back pain. The procedures were performed at a solo practitioner private practice from July 2016 to April 2018. Patients who did not have at least one-month follow-up after the first injection were excluded. All treatments were prescribed on an individual basis, as recommended by a physician. Written informed consent was obtained prior to each treatment.
As stated in our previous knee osteoarthritis publication, [24] if a patient at our clinic requires multiple injections, we direct them to receive injections approximately fourteen days apart, however, scheduling conflicts often cause injection intervals more than fourteen days. At the fourteen day time period, there is growth factor secretion from various cell types that participate in the late phases of wound healing, which can enhance tissue regeneration [25, 26] .
Patients were instructed not to use non-steroidal anti-inflammatory drugs during treatment since they significantly impair platelet function [27] . In addition, they were instructed not to participate in any strenuous physical activity for the duration of treatment. Patient characteristics can be found in Table 1 . This study was constructed to follow all ethical guidelines directed by the Declaration of Helsinki.
Procedure 48-cc of blood was drawn into six 8.5mL ACD solution A tubes. The blood was then spun in a centrifuge, and the top layer without visible red blood cells was isolated to yield 12-cc PRP. The PRP was then split into 4-cc portions and was added to three 6-cc syringes. 2-cc of Lidocaine was added to each syringe to ensure less post-injection stiffness. The injection sites were sterilized with 4% Hibiclens. The PRP was injected by the physician into the tender or painful A c c e p t e d M a n u s c r i p t areas along the enthesis of the insertion of the quadratus lumborum, thoracodorsal fascia, iliac crest, interspinous and supraspinous ligaments, gluteus attachments to the pelvis, sacroiliac ligaments, etc, as determined per patient's complaints and tenderness.
Outcomes
The outcomes of interest in this study were changes to resting pain and active pain (numerical pain scale [NPS]), overall improvement (percentage scale), and function (scored questionnaire)
as seen in Figure 1 . Data was collected at follow-ups after each treatment and were performed at approximately one month, three months, six months, and annually after the first injection. The functionality portion of the questionnaire, which assessed the degree of difficulty in performing daily activities, was based on 10 of 20 activities assessed in the Lower Extremity Functional Scale, [28] but also included a "not applicable (N/A)" response option. This scale has been shown to be a reliable functionality questionnaire for LBP [29] . The NPS to assess resting and active pain used a scale of 0 (no pain) to 10 (extreme pain) [30] . Lastly, the form included a subjective measure of how much overall improvement the patient experienced following treatment on a scale of 0% to 100%.
Statistical Analysis
Baseline and postintervention data were compared using means and standard deviations. Each follow-up response was compared with its corresponding baseline response using the Wilcoxon signed rank test. Intergroup comparisons were performed using the Wilcoxon sum rank test.
Covariates were not accessed in this report. Statistical significance was set at P less than 0.05 and statistical analysis was performed using R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results
A c c e p t e d M a n u s c r i p t When patients were asked a percentage of overall improvement they also reported successive increases. Patients who received one treatment reported 36.33% total overall improvement, two treatment patients reported 46.17% total overall improvement, and three treatment patients reported 54.91% total overall improvement. 35 out of 67 patients experienced at least 50% overall improvement compared to baseline.
In terms of functionality score, two-treatment patients experienced less difficulty performing daily activities reporting a 6.16 (P=<0.001) increase, which is a 28.51% increase compared to baseline. Three treatment patients reported a 7.00 (P<0.001) increase in A c c e p t e d M a n u s c r i p t functionality score, which is a 35.32% increase compared to baseline. The two and threetreatment groups experienced greater functionality score increases compared to the one-treatment group.
Discussion
Our study demonstrated that one, two or three PRP treatments were effective in significantly reducing active pain in the lower back. Additionally, functionality scores were significantly increased showing that patients were able to quickly return to everyday activities. Patients experienced an improvement in resting pain and functionality score after the one treatment, however, statistical significance was demonstrated only after the second and third treatments.
Yet, self-reported mean total improvement was 36.33%, 46.17%, and 54.91% at the first, second and third treatments, respectively, suggesting an immediate clinical benefit.
Traditional treatments for chronic non-specific LBP include pharmacologic, steroid, or surgical interventions; however, the evidence for their efficacy is lacking and insufficient. For example, long-term controlled studies found that pharmacologic treatment for chronic LBP may only provide three months of relief and the overall quality of evidence was low [31] . Steroid injections are another common treatment, yet the FDA issued a drug safety warning in 2014 stating the effectiveness of steroid use has not been established and that there is potential for serious adverse effects. Furthermore, studies have shown that steroid injections were not suggested for chronic LBP lasting greater than six months and, overall, did not improve pain or disability [32, 33] .
PRP is fast, non-invasive procedure that has been studied as an alternative treatment modality for low back pain and musculoskeletal injuries in the recent decade. The physiologic complexity of PRP bestows characteristics intriguing to investigators that involve immunomodulatory effects as well as angiogenic properties that facilitate healing. The exact A c c e p t e d M a n u s c r i p t mechanism of PRP is not known, but current research points to cytokines, growth factors and other proteins as the main medium through which PRP works [34] . Specifically, studies have shown that PRP contains vascular endothelial growth factor, epidermal growth factor, transforming growth factor β-1, platelet-derived growth factor, hepatocyte growth factor, insulinlike growth factor-I, basic fibroblast growth factor, and connective tissue growth factor responsible for significant tissue proliferation [34] [35] [36] . PRP also contains certain chemokines and cytokines that are involved in the innate inflammatory and immunologic response that facilitate healing [37] . Simultaneously, PRP modulates gene expression of specific chemokines that serve to regulate the immuno-inflammatory reaction, preventing disproportionate responses and reducing pain [22] .
Tissue healing is a complex mechanism acting through multiple physiologic pathways that may require time for molecular recruitment to reach satisfactory levels to observe clinically beneficial effects. Our results indicated significant improvement in all measurable outcomes after a series of two treatments and showed continued improvement after three treatments. Based on these results, it could be hypothesized that with each successive treatment further improvement may be demonstrated due to increased molecular involvement. Furthermore, combining other treatment modalities known to act through similar pathways may enhance the effects of PRP and increase the rate of healing. For example, investigators have demonstrated that hyperbaric oxygen combined with platelet concentrate increases the rate of bone healing. [38] Further research is needed to explore these avenues; however, the promise of PRP in the treatment of chronic LBP and other degenerative health issues offers hope to patients that have failed conservative treatment and are unable to find relief of their symptoms.
A c c e p t e d M a n u s c r i p t
The limitations of our study include the limited sample size in the group of patients that received a total of one treatment. The improvement in resting pain and functionality scores were not statistically significant, but perhaps with a larger sample size, pain scores may be significant even after one treatment. Another limitation to our study was the population studied. According to epidemiologic studies, risk factors for chronic lower back pain include low educational status and lower socioeconomic levels [39, 40] . Most insurance companies do not cover PRP and subsequently our patient population may not be representative of the general population suffering from chronic low back pain. In addition, the conclusions of this study were limited by not accounting for all variables that may have influenced patient outcomes, such as comparing age and BMI between groups. However, we plan on addressing different covariates in a separate study at a later date. The subjectivity of the measured variables may have introduced response bias and there was no control group to account for a placebo effect of the injections. Further randomized-controlled studies with larger sample sizes and longer follow-ups are warranted to further validate these results.
Conclusion
Our study demonstrated that PRP therapy reduced pain and increased functionality in patients with chronic non-specific LBP. The results of the study offer promise to patients that have failed conservative modalities and seek a quick, non-invasive treatment. Further research is warranted to determine the efficacy of widespread implementation of PRP as the standard of care for chronic non-specific LBP and other related chronic health issues.
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